The Readout LOUD

The Readout LOUD Adam Feuerstein and Allison DeAngelis

STAT Plus: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama

The Readout LOUD Allison DeAngelis and Adam Feuerstein

STAT Plus: Listen: A new obesity startup, an acquisition gone wrong, & the future of Teladoc

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s big deal, biotech’s red numbers, & an industry history lesson

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Live! From the STAT Breakthrough Summit East

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

A dilemma in ALS, the first MASH drug, & why gene therapy is hard

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

VC turmoil, GLP-1 competition, & the war on recovery

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Legal insider trading, booming biotech stocks, & the next GLP-1

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Humira’s legacy, CEO symbolism, and genomic surgery

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

AI in medicine, detangling hype, and Icelandic DNA

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

The plight of the VC, Gilead’s latest setback, & more M&A

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Biotech layoffs, slumping stocks, and a 2024 preview

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Live! From JPM 2024

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

2023 in review, CEO report cards, and a look at the year ahead

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

CRISPR history, biotech struggles, & a big week for deals

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

The Readout LOUD Allison DeAngelis and Adam Feuerstein

A CRISPR milestone, algorithms amok, & biotech mixology

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Lilly’s obesity drug, the power of radiation, & a biotech implosion

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

ESMO highlights, Roivant’s big deal, & biotech VC on the rise

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Live from the 2023 STAT Summit

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Merger Mondays, Ozempic panic, & CRISPR’d pigs

The Readout LOUD Damian Garde and Allison DeAngelis

Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump

The Readout LOUD Damian Garde and Allison DeAngelis

A thorny ALS debate at the FDA, and the promise of artificial wombs

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Covid’s latest surge, Alnylam at the FDA, & the end of an era